The epithelial-mesenchymal transition (EMT), a prerequisite for cancer progression and metastasis formation, is regulated not only at the transcriptional but also at the post-transcriptional level, including at the level of alternative pre-mRNA splicing. Several recent studies have highlighted the involvement of splicing factors, including epithelial splicing regulatory proteins (Esrps) and RNAbinding Fox protein 2 (Rbfox2), in this process. Esrps regulate epithelial-specific splicing, and their expression is downregulated during EMT. By contrast, the role of Rbfox2 is controversial because Rbfox2 regulates epithelial as well as mesenchymal splicing events. Here, we have used several established cell culture models to investigate the functions of Rbfox2 during EMT. We demonstrate that induction of an EMT upregulates the expression of Rbfox2, which correlates with an increase in Rbfox2-regulated splicing events in the cortactin (Cttn), Pard3 and dynamin 2 (Dnm2) transcripts. At the same time, however, the epithelial-specific ability to splice the Enah, Slk and Tsc2 transcripts is either reduced or lost completely by Rbfox2, which might be due, in part, to downregulation of the expression of the Esrps cooperative factors. Depletion of Rbfox2 during EMT did not prevent the activation of transforming growth factor-b signaling, the upregulation of mesenchymal markers or changes in cell morphology toward a mesenchymal phenotype. In addition, this depletion did not influence cell migration. However, depletion of Rbfox2 in cells that have completed an EMT significantly reduced their invasive potential. Taken together, our results suggest that during an EMT, Rbfox2-regulated splicing shifts from epithelial-to mesenchymal-specific events, leading to a higher degree of tissue invasiveness.
INTRODUCTION
During epithelial-mesenchymal transition (EMT), cancer cells originating from a primary carcinoma of epithelial origin gain migratory and invasive capabilities and acquire a mesenchymal morphology. 1, 2 It is thought that EMT promotes invasion and metastases; therefore, understanding the molecular basis of an EMT is crucial for developing effective cancer therapies. Although it was initially thought that an EMT is regulated mainly at the transcriptional level, it is now widely accepted that posttranscriptional regulation, including alternative pre-mRNA splicing, has an important role as well. 3 The RNA-binding Fox (Rbfox) proteins (Rbfox1, Rbfox2 and Rbfox3) are regulators of alternative splicing. All three proteins contain a central RNA-recognition motif that recognizes the consensus sequence (U)GCAUG in the introns that flank target exons. Rbfox proteins promote exon skipping when they bind upstream of the alternative exon but inclusion when they bind downstream of this exon. [4] [5] [6] [7] [8] [9] [10] Although all Rbfox proteins bind to the (U)GCAUG sequence, because of their differing expression patterns these proteins are only partially redundant in vivo. Rbfox1 is expressed in the brain, heart and ovaries, and Rbfox3 is expressed exclusively in the brain. By contrast, Rbfox2 is more widely expressed and is the only member of the Rbfox family that is found in mammary cell lines as well as in normal and breast cancer tissue. [11] [12] [13] [14] EMT-associated splicing is most likely regulated by several splicing factors, including Rbfox2, Esrps, Celf, Mbnl, hnRNPs, Sam68 and SF2/ASF. [15] [16] [17] Epithelial splicing regulatory proteins 1 and 2 (Esrp1 and Esrp2) are important regulators of epithelialspecific splicing choices and are downregulated during the EMT. Of note, siRNA-mediated depletion of Esrps in epithelial cells causes EMT-like morphological changes. 18 The alternative splicing of a subset of Esrp target mRNAs is co-regulated by Rbfox2. Thus, both Esrps and Rbfox2 are essential regulators for epithelialspecific splicing of fibroblast growth factor receptor 2 and Enah. 4, 19, 20 In contrast to the Esrps, the role of Rbfox2 during the EMT is less well understood. Despite its established importance for epithelial-specific splicing of the targets mentioned above, Rbfox2 expression was found to increase moderately following EMT in an established in vitro model, suggesting an active function during an EMT. In agreement with this hypothesis, depletion of Rbfox2 in mesenchymal cells leads to a partial reversion toward an epithelial phenotype in the same model. Moreover, numerous EMT-regulated skipped exons have been found to overlap with Rbfox2 CLIP-Seq clusters in human cell lines. 15 Thus, although it seems clear that Rbfox2 promotes epithelial-specific splicing in some cases, it appears to promote mesenchymal-specific splicing in others.
In our study, we have used two transforming growth factor-b (TGFb)-inducible in vitro models to study, in detail, the role of Rbfox2 during an EMT. The expression of Rbfox2 increased moderately following induction of the EMT and Rbfox2 regulated EMT-associated splicing. Rbfox2-depleted cells underwent an EMT with no obvious morphological differences from the control cells. Yet, cell invasion was significantly reduced in Rbfox2-depleted tumor cells, suggesting that Rbfox2 is essential for epithelial cells to gain invasive properties during an EMT.
RESULTS

Two different
Rbfox2 isoforms are expressed during EMT To study the functions of Rbfox2 in the TGFb-dependent EMT, we used two mouse cell lines, which both underwent a complete EMT upon treatment with TGFb [21] [22] [23] ( Figure 1a) . We used the wellcharacterized non-transformed mammary epithelial cell line NMuMG and an epithelial murine breast cancer cell line, PY2T, Figure 1 . Rbfox2 expression in TGFb-dependent EMT-models: (a) morphological changes of NMuMG and PY2T cells cultured in the presence of 2 ng/ml TGFb1 for 3 days. (b) Real time RT-PCR assays of Rbfox2 expression in NMuMG and PY2T cell lines at different time points after induction of an EMT by treatment with 2 ng/ml TGFb1. Total RNA was isolated from NMuMG and PY2T cells as indicated and was reversed transcribed to cDNA using random hexamer oligos. The expression of Rbfox2 was measured by real time RT-PCR, and mRNA expression was normalized to Tbp expression. (c) Immunofluorescence analyses of Rbfox2 subcellular localization in NMuMG and PY2T cell lines before and after induction of the EMT by TGFb-treatment. NMuMG and PY2T cells were treated with or without 2 ng/ml TGFb1 for 3 days and subjected to immunofluorescence analyses using a Rbfox2-specific antibody. As a control Rbfox2-specific siRNAs were transfected. (d-g) Identification of Rbfox2 isoforms expressed in NMuMG and PY2T cells. (d) Odyssey Immunoblotting analysis of Rbfox2 in different cell lines before and after induction of an EMT. Cells were lysed at the indicated time points and used for immunoblotting analysis using an antibody that detects all known Rbfox2 isoforms. b-actin was used as the loading control. Upper panel, representative immunoblot; lower panel, quantification of three independent experiments. (e) Arrangement of alternative first exons in the Rbfox2 gene. Solid bars, exons. Lines between exons, introns. There are four alternative first exons in the Rbfox2 gene (1A, 1D, 1E, 1F). Arrows, the primer pairs used in the RT-PCR experiments. (f ) RT-PCR assay of Rbfox2 isoforms expressed in NMuMG and PY2T cells. Total RNA was isolated from NMuMG and PY2T cells as indicated and was reversed transcribed to cDNA using random hexamer oligos. The cDNA was then amplified by PCR using primers, as indicated in panel (e), and the products were resolved in 1% agarose gels. Subsequently, the products were cloned and sequenced. Asterisks, unspecific products. (g) Fortyeight hours after transfection with the indicated siRNAs, cells were lysed and subjected to immunoblotting analysis using an antibody that detects all known Rbfox2 isoforms; *Po0.05; ***Po0.001.
which was established from a mammary tumor of a Polyoma middle-T transgenic mouse. 24 In both the cell lines, Rbfox2 expression increased moderately, by 1.5-2-fold, following induction of an EMT by TGFb treatment, suggesting an active function of this protein during EMT (Figure 1b) . Of note, upon removal of TGFb Rbfox2 expression decreased back to the level of untreated cells, indicating that this expression change was reversible (Supplementary Figure S1A) . Immunofluorescence experiments using a commercially available anti-Rbfox2 antibody revealed that Rbfox2 localization was mainly restricted to the nucleus in both NMuMG and PY2T cells and that this localization did not change after induction of an EMT, which is in accordance with the known function of Rbfox2 as an alternative splicing factor (Figure 1c) .
The transcription of the Rbfox2 gene is initiated from several alternative promoters, producing Rbfox2 isoforms that differ in their N-terminal sequences. Although the functional differences of the different isoforms are poorly understood, it has been suggested that different isoforms may regulate alternative splicing with varying efficiencies. 10 Moreover, dominant-negative Rbfox2 isoforms lacking part of the RNA recognition motif have been described. 25 Therefore, a hypothetical switch in the production of Rbfox2 isoforms during an EMT could lead to a shift in alternative splicing of target exons. Immunoblotting analysis using an Rbfox2-specific antibody detected two Rbfox2 isoforms in lysates of both NMuMG and PY2T cell lines before and after induction of an EMT (Figure 1d ). Quantification of the two isoforms revealed that the increase in Rbfox2 expression after the induction of an EMT was mainly due to an increase in the smaller Rbfox2 isoform (Figure 1d ). To identify these isoforms, we carried out isoformspecific reverse transcriptase-PCR (RT-PCR) by combining forward primers located in each of the four alternative first exons of the Rbfox2 gene with a reverse primer located near the 3 0 end (Figure 1e ). Although strong products appeared when forward primers corresponding to first exons 1A and 1F were used, primers located in first exons 1D and 1E did not reveal any products in the RT-PCR experiments (Figure 1f ). To test for the presence of dominant-negative Rbfox2 isoforms, we performed RT-PCR experiments before and after induction of an EMT by TGFb treatment of NMuMG and PY2T cells. Remarkably, the skipping of exon 6, the splicing event leading to the production of dominantnegative Rbfox2 isoforms, was not detected in NMuMG cells before or after induction of an EMT in 21 and 25 sequenced clones, respectively. It was also not detected in PY2T cells after induction of an EMT in 17 sequenced clones, and it was detected in only 1 out of 16 sequenced clones in PY2T cells before induction of an EMT (data not shown). These results indicate that the skipping of exon 6 is a rare event in our EMT models, which should not influence Rbfox2 activity. To further confirm that the Rbfox2 isoforms identified by immunoblotting analysis were produced from transcripts containing Rbfox2 exons 1A or 1F, siRNAs specifically targeting each of these exons were transfected into NMuMG cells. Immunoblotting analysis of the obtained lysates showed the disappearance of the expected isoforms when compared with a control knockdown or a knockdown of all Rbfox2 isoforms (Figure 1g ).
The increase of isoform 1F and the decrease of isoform 1A during EMT could lead to a switch in the splicing of specific Rbfox2 targets. Hypothetically, the isoform 1A could mediate epithelial splicing events and isoform 1F could promote mesenchymal splicing events. To test whether the differential expression of the two isoforms was controlled by transcriptional start site selection, we carried out quantitative RT-PCR experiments with primers specifically detecting isoforms 1A or 1F. In NMuMG cells, isoform 1A was indeed significantly downregulated and isoform 1F was significantly upregulated at the RNA level 3 days and 4-5 weeks after induction of an EMT, suggesting that in this cell line a switch in isoform expression was mediated at the transcriptional level introns. Isoform-specific primers were designed to correspond either entirely to the respective alternatively spliced exons or to exonexon junctions. Upper and lower panels show expression and splicing changes, respectively; *Po0.05; **Po0.01; ***Po0.001.
(Supplementary Figure S2A) . In PY2T cells, however, this was not the case. Rather, both isoforms were upregulated after induction of an EMT (Supplementary Figure S2A) . To test whether the decrease in isoform 1A expression that we had observed in NMuMG cells was a cell-specific effect, we analyzed the expression of Rbfox2 isoforms in another EMT model. MTdeltaEcad cells were generated by establishing a cell line from the mammary tumors of MMTV-Neu transgenic mice, in which both E-cadherin alleles were flanked by LoxP recombination sites (MTflEcad). MTdeltaEcad cells were generated from this cell line by expressing Cre recombinase, thereby leading to genetic ablation of E-cadherin, which was followed by an upregulation of mesenchymal markers and a change in cell morphology toward a fibroblastic appearance. 23 Expression of both Rbfox2 isoforms increased in the mesenchymal MTdelEcad cells at both RNA and protein levels when compared with the epithelial MTflEcad cells (Supplementary Figure S2A and B). These results suggest that a switch in Rbfox2 isoform expression might not be a general hallmark of an EMT. Rather, it might be a cell type-specific event or be important early after EMT induction. A further analysis of putative isoform-specific functions turned out to be technically challenging because transfection of siRNAs targeting the isoform-specific regions caused various off-target effects.
The presence of Rbfox2 does not prevent mesenchymal-specific splicing in the Enah, Slk and Tsc2 transcripts Rbfox2 promotes epithelial-specific splicing in a number of transcripts. Exons 11a, 13 and 25 of the Enah, STE20-like kinase (Slk) and tuberous sclerosis protein 2 (Tsc2) transcripts, respectively, are included in epithelial cells and skipped in mesenchymal cells. 15 To test whether the presence of Rbfox2 could prevent mesenchymal-specific splicing in our models following TGFb treatment, we studied the splicing changes in these target exons. Thus, we developed an exon-specific quantitative RT-PCR assay using primers that either specifically anneal to the alternative exons or span the exon-exon junctions (Supplementary Table S2 ). In contrast to NMuMG cells, PY2T cells upregulated Enah expression dramatically 4-5 weeks following TGFb treatment. Interestingly, the presence of Rbfox2 could not prevent an increased skipping of exon 11a of the Enah transcript in these cells, which was most evident 4-5 weeks following TGFb treatment (Figure 2a) . Consistently, the presence of Rbfox2 could also not prevent an increased skipping of exon 13 of the Slk transcript following TGFb treatment in NMuMG and PY2T cells and of exon 25 of the Tsc2 transcript following TGFb treatment in PY2T cells (Figures 2b and c) . All these splicing changes reversed back to levels of untreated cells upon removal of TGFb, however, the kinetics of this reversal varied between the different exons (Supplementary Figure S1B) . To test whether Rbfox2 had lost activity towards these targets in TGFb-treated cells, we transfected Rbfox2 siRNAs into NMuMG and PY2T cells before and after 3 days and after 4-5 weeks of TGFb treatment. Knock down of Rbfox2 in NMuMG cells led to a decrease of Enah exon 11a inclusion at all time points tested, whereas in PY2T cells, knock down of Rbfox2 only affected the splicing of Enah exon 11a before and after 3 days but not after 4-5 weeks of TGFb treatment (Figure 3a ). The loss of activity of Rbfox2 toward splicing of exon 11a of the Enah transcript in PY2T cells 4-5 weeks after TGFb treatment suggests that Rbfox2, although necessary, is not sufficient to regulate this splicing event. In contrast to splicing of Enah exon 11a, knock down of Rbfox2 in PY2T cells led to a further decrease of alternative exon inclusion of the Slk and Tsc2 transcripts even after 4-5 weeks following TGFb treatment (Figures 3b and c) . This indicates that, although Rbfox2 retains activity towards these targets, it cannot prevent an increased skipping of these exons following TGFb treatment. Other splicing factors that act in a cooperative or antagonistic fashion may co-regulate splicing of the epithelial-specific exons in the Enah, Slk and Tsc2 transcripts. In agreement with this suggestion, it has been shown that the splicing of exons 11a, 13 and 25 of the Enah, Slk and Tsc2 transcripts, respectively, is not only controlled by the binding of Rbfox2 to conserved UGCAUG motifs but also by the binding of Esrp1 and Esrp2 to UGG-rich motifs. Hence, a cooperative function of Rbfox2 and Esrps in the splicing of these exons has been proposed. 18 We found that although NMuMG cells expressed exclusively Esrp2 (Supplementary Figure S4B 26 ), PY2T cells expressed both Esrp1 and Esrp2 before induction of an EMT. Of note, 4-5 weeks after induction of an EMT, PY2T cells displayed Figure S4A and B) . These results suggest that Esrps may act cooperatively with Rbfox2 in TGFb-treated NMuMG cells. However, other, as yet to be identified, factors may, in addition, co-regulate the inclusion or skipping of the epithelial-specific exons.
Rbfox2 regulates EMT-associated alternative splicing An increase in Rbfox2 expression during the EMT should be reflected by an upregulation of Rbfox2-regulated splicing choices. We chose three different Rbfox2 target exons as model systems to study Rbfox2-regulated splicing during EMT. Several studies have shown that Rbfox2 regulates the skipping of exon 18 and a 12-nt exon in Pard3 and Dnm2 gene expression, respectively, as well as the inclusion of exon 11 in Cttn gene expression. 4, 7 Although the functional consequences of the alternative splicing events of the Pard3 and Cttn mRNAs are unclear, the 12-nt exon of the Dnm2 transcript that is skipped after the induction of EMT has been functionally linked to the localization and functioning of the GTPase Dnm2 at the GOLGI apparatus. How this affects the induction or progression of the EMT, however, remains unclear. The skipping of exon 18 and of the 12-nt exon of the Pard3 and Dnm2 transcripts, respectively, was enhanced in NMuMG and PY2T cells 3 days and 4-5 weeks following TGFb treatment (Supplementary Figure S4A and B) . Cttn exon 11 inclusion was increased in NMuMG cells 3 days and 4-5 weeks after induction of an EMT and in PY2T cells 4-5 weeks after induction of an EMT (Figure 4c ). All splicing changes reversed back to the levels of untreated cells upon removal of TGFb; however, the kinetics of this reversal varied between the different exons (Supplementary FigureS 1B) . Conversely, the skipping of exon 18 and of the 12-nt exon of the Pard3 and Dnm2 transcripts, respectively, and the inclusion of Cttn exon 11 was reduced significantly in NMuMG and PY2T cells transfected with Rbfox2 siRNAs at all time points analyzed (Figures 5a-c) , indicating that Rbfox2 is an important regulator of EMT-driven alternative splicing. To exclude the possibility of promiscuous effects on alternative splicing in Rbfox2 knockdown cells, we analyzed the splicing of exons v8-v10 in the CD44 transcript, which is not a described Rbfox2 target. Although the skipping of exons v8-v10 was enhanced in both the NMuMG and PY2T cells following TGFb treatment, the knock down of Rbfox2 did not alter the splicing of these exons in any of the two cell lines (Supplementary Figure S3A and B) . To test whether Rbfox2 expression was essential for acquiring a mesenchymal phenotype, we depleted Rbfox2 from both the cell lines by transfection of specific siRNAs. Then, 48 h after transfection, an EMT was induced by TGFb treatment. Immunoblotting analysis revealed efficient knock down of Rbfox2 under these conditions (Figure 6a ). Several observations indicated that cells transfected with Rbfox2 siRNA underwent an EMT. Both Rbfox2-depleted cells and cells treated with control siRNAs upregulated Phospho-Smad2 1 h after TGFb treatment, indicating that TGFb signaling could be activated in these cells (Figure 6b) . Moreover, the upregulation of several EMT markers was unaffected by the depletion of Rbfox2, as evidenced by western blot analyses using specific antibodies. No difference was detected in the expression of N-cadherin and vimentin in Rbfox2 knockdown cells when compared with control knockdown cells (Figures 6c and d) . Morphologically, Rbfox2-depleted cells were indistinguishable from control siRNA-transfected cells and acquired a spindle-shaped fibroblastic morphology upon TGFb treatment. Both control knockdown and Rbfox2 knockdown cells formed stress fibers and focal adhesions, as evidenced by phalloidin and vinculin staining of NMuMG and PY2T cells 48 h after TGFb treatment (Figures 6e and f) . In summary, our results suggest that Rbfox2 is not essential for cells to acquire a mesenchymal phenotype after induction of an EMT.
Depletion of Rbfox2 leads to reduced invasion Important consequences of EMT include altered cell migration and invasion. To assess the effect of Rbfox2 depletion on cell migration and invasion, we transfected control and Rbfox2 siRNAs into NMuMG and PY2T cells that had been exposed to long-term TGFb treatment (4-5 weeks) and thus had completed an EMT (Figure 7a ). Forty-eight hours after transfection, the cells were used for morphological analysis and for in vitro migration and invasion assays. Morphologically, Rbfox2-depleted cells were indistinguishable from control siRNA-transfected cells ( Supplementary Figure S5A and B; data not shown). Two approaches were used to study migration: wound-healing assays and transwell migration assays (Figures 7b and c; data not shown). In neither of the two approaches could we detect a difference in the migration of NMuMG or PY2T cells between the control knockdown and Rbfox2 knockdown cells, suggesting that Rbfox2 depletion does not impair the migratory behavior of cells that have undergone an EMT.
To assess the effect of Rbfox2 depletion on cell invasion, we used an invasion assay in Matrigel-coated transwell chambers. We found no differences in cell invasion by NMuMG cells between the control siRNA and Rbfox2 siRNA-transfected cells (Figure 7d) . Interestingly, PY2T cells depleted of Rbfox2 showed significantly reduced invasion compared with the control knockdown cells (Figure 7e ), indicating that Rbfox2-dependent splicing is important for PY2T cells to maintain an invasive phenotype. To test whether the reduced invasion after Rbfox2 knock down was specific to PY2T cells or was a general phenomenon, we repeated the invasion assays with MTdeltaEcad cells. Immunoblotting analysis revealed efficient knock down of Rbfox2 in these cells (Figure 7a ). As observed in PY2T cells, Rbfox2 depletion reduced the invasiveness of MTdeltaEcad cells significantly, indicating that Rbfox2 regulates invasiveness in different experimental systems (Figure 7f ).
Rbfox2 targets promote the invasive phenotype Aberrant splicing of mesenchymal-specific Rbfox2 targets might be causative for the reduced invasiveness of Rbfox2 knockdown cells. To identify Rbfox2 targets with known functions during invasion, we screened the available data sets of EMT-associated splicing. 15 This screen identified 28 transcripts whose splicing patterns changed during EMT and whose protein products have a described function during invasion. Thirteen of the 28 transcripts contained conserved Rbfox2-binding sites in their introns or exons (Table 1) . Of note, this list of 13 transcripts included splicing changes in the mesenchymal-specific Rbfox2 target Dnm2 and the epithelial-specific Rbfox2 targets Enah, Slk and Tsc2, which we had already verified in our models in the quantitative RT-PCR assay (Figures 2b, 3b , 4a-c and 5a-c). In addition, the mesenchymalspecific Rbfox2 targets Pard3 and Cttn, which were not included in the data set but identified in our quantitative RT-PCR assay, are well-known regulators of invasion (Table 1 27,28 ). In summary, 6 of the overall 15 transcripts with conserved Rbfox2-binding sites were mesenchymal-specific Rbfox2 targets (Table 1) .
DISCUSSION
We have used several cellular systems to study the functions of the alternative splicing factor Rbfox2 during EMT. We show that induction of an EMT is associated with the increased expression of Rbfox2 in all the cell lines tested, which correlates with the upregulation of Rbfox2-regulated splicing events in the Pard3, Dnm2 and Cttn transcripts, whereas the epithelial-specific ability to splice the Enah, Slk and Tsc2 transcripts is reduced or lost completely by Rbfox2. Notably, although depletion of Rbfox2 before the onset of an EMT does not inhibit this process, the depletion of Rbfox2 after cells have completed an EMT significantly reduces the invasiveness of these cells.
The moderate upregulation of Rbfox2 expression that we observed after induction of an EMT is in agreement with a recently published study by Shapiro et al., 15 which showed that the expression of Rbfox2 increases by approximately 15% following the EMT in a mammary epithelial cell line that undergoes an EMT after the induction of Twist expression by tamoxifen treatment. However, as we can further show, the sole increase in Rbfox2 expression is not always predictive of an increase in Rbfox2-regulated splicing events. Thus, Rbfox2-dependent epithelialspecific splicing of the Enah and Slk transcripts did not increase in NMuMG cells, and Rbfox2-dependent splicing of the Enah, Slk and Tsc2 transcripts was completely abolished or reduced in PY2T cells. Skipping exons 11a, 13 and 25 of the Enah, Slk and Tsc2 transcripts, respectively, during EMT has been observed in other models as well. 15, 19 Although these splicing events are certainly regulated by Rbfox2, other splicing factors that act cooperatively may be equally important. The splicing of exon 11a of the Enah transcript is controlled by a conserved sequence located approximately 1.8 kb downstream of this exon. Similar to the Rbfox2-binding site UGCAUG, this sequence contains UGG-rich motifs, which are bound by the epithelial-specific splicing factors Esrps to promote the inclusion of exon 11a. Also, inclusion of exons 13 and 25 of the Slk and Tsc2 transcripts, respectively, is Figure 6 . NMuMG and PY2T cells undergo an EMT in the absence of Rbfox2. (a) Efficient Rbfox2 depletion in NMuMG and PY2T cells using Rbfox2-specific siRNAs. Forty-eight hours after the transfection of specific siRNAs, cells were lysed and subjected to immunoblotting analysis using a Rbfox2-specific antibody. Antibodies detecting Gapdh (glyceraldehyde 3-phosphate dehydrogenase) or Actin were used as loading controls. (b) Activation of the TGFb-pathway in the absence of Rbfox2. Forty-eight hours after the transfection of specific siRNAs, NMuMG and PY2T cells were treated with 2 ng/ml TGFb1 for 1 h. Then, the cells were lysed, and western blot analyses were performed with antibodies specifically detecting Smad2/3 or phospho-Smad2. (c, d) Upregulation of N-cadherin (Ncad) and vimentin. Forty-eight hours after transfection with specific siRNAs, NMuMG or PY2T cells were treated with 2 ng/ml TGFb1 for another 48 h. Then, the cells were lysed, and immunoblotting analysis were performed using antibodies specifically detecting Ncad (c) or vimentin (d). (e, f) Rbfox2-depleted cells form stress fibers and focal adhesions. NMuMG and PY2T cells plated on coverslips were treated as described in panel (c) and processed for immunofluorescence analysis using an Rbfox2-specific antibody to control for knockdown efficiency, a vinculin-specific antibody to analyze the formation of focal adhesions and Phalloidin488 to visualize actin stress fibers. Untreated cells are shown for comparison.
promoted by Esrps. 18 In contrast to Rbfox2, the expression of the Esrps, that is, Esrp1 and Esrp2, has been reported to be downregulated upon induction of an EMT. 18 Although the expression of both Esrps strongly decreased in PY2T cells that had completed an EMT, the expression of Esrp2, the only expressed Esrp in NMuMG cells, decreased by approximately 50%. The decrease in expression of Esrps correlated with the decrease in alternative exon inclusion in the Enah, Slk and Tsc2 transcripts 4-5 weeks following TGFb treatment in PY2T cells, suggesting that both Rbfox2 and Esrps are necessary, but not sufficient, to regulate these splicing events. In addition, other splicing factors might be important as well. Three days after induction of an EMT in PY2T cells, Esrps were still expressed at the same levels as in untreated cells. However, the inclusion of exons 11a and 25 of the Enah and Tsc2 transcripts, respectively, but not of exon 13 of the Slk transcript had already decreased at this time point. In NMuMG cells, inclusion of Enah exon 11a did not decrease at any time point following TGFb treatment and inclusion of Tsc2 exon 25 even increased 3 days following TGFb treatment. By contrast, inclusion of Slk exon 13 decreased strongly after the induction of an EMT in NMuMG cells. Changes in expression of other, as yet to be identified, splicing factors that specifically regulate inclusion or skipping of the respective exons may account for these differences.
In contrast to the epithelial-specific splicing choices, Rbfox2-dependent mesenchymal-specific splicing of the Pard3, Dnm2 and Cttn transcripts increased following the induction of an EMT and decreased in Rbfox2 knockdown cells. These results indicate that Rbfox2 is an important regulator of mesenchymal-specific splicing choices during EMT. and MTdeltaEcad cells using Rbfox2-specific siRNAs. NMuMG or PY2T cells were treated with 2 ng/ml TGFb1 for 4-5 weeks and then transfected with control or Rbfox2-specific siRNAs. Forty-eight hours after the transfection of specific siRNAs, cells were lysed and subjected to immunoblotting analysis using a Rbfox2-specific antibody. An antibody detecting Actin was used as loading control. (b,c) Scratch wound closure assay. NMuMG (b) or PY2T cells (c) were treated with 2 ng/ml TGFb1 for 4-5 weeks and then transfected with control or Rbfox2-specific siRNAs. Forty-eight hours after transfection, the cells were seeded into the wells of culture inserts (Ibidi) at a density of 6 Â 10 5 cells/ml. Twenty-four hours after seeding, the culture inserts were removed. Microphotographs were taken at 0, 6 and 24 h. (d-f ) Invasion assays. NMuMG (d) or PY2T cells (e) were treated with 2 ng/ml TGFb1 for 4-5 weeks. Then, NMuMG, PY2T or MTdeltaEcad cells (f ) were transfected with control or Rbfox2-specific siRNAs. Forty-eight hours after transfection, transwell invasion assays were carried out over 24 h; *Po0.05; **Po0.01.
Although Shapiro et al. 15 found a partial reversion toward an epithelial phenotype when they stably transfected Rbfox2-specific shRNAs, we could not detect such a phenotypic change in any of the cell lines that had been depleted of Rbfox2 after an EMT was completed. Different experimental approaches used in the two studies may be one reason for this. In addition, cell type-specific changes in splicing patterns after depletion of Rbfox2 may account for the observed phenotypic differences. Despite no obvious differences in cell morphology, cell invasion was significantly reduced when Rbfox2 was depleted from PY2T and MTdeltaEcad cells but was not reduced when Rbfox2 was depleted from NMuMG cells. However, even in the presence of Rbfox2, the non-transformed NMuMG cells were much less invasive than any of the other cell lines tested, which could explain why invasion could not be further decreased in this cell line upon depletion of Rbfox2. Alternative splicing has been shown to contribute to every aspect of tumorigenesis, including resistance to apoptosis, and promotion of metastasis, angiogenesis and invasion. 29 There are several examples of alternative splicing in genes that are involved in invasion, including CD44, Enah, TP53INP2 and others. [29] [30] [31] [32] [33] Rbfox2 promotes splicing of the epithelial isoform of Enah and, therefore, this splicing event seems unlikely to mediate the invasive function of Rbfox2. To our knowledge, none of the other splicing events has been shown to be regulated by Rbfox2. Thus, the modulation of cell invasion by Rbfox2 may be mediated by alternative splicing events in other genes that have yet to be identified. In this study, we identified six mesenchymal-specific Rbfox2 targets, which are involved in invasion. Future studies will show how splicing changes in these targets may modulate the invasive phenotype.
It has recently been demonstrated that many cancer-associated alternative splicing events are linked to Rbfox2-binding sites, that Rbfox2 is downregulated in ovarian cancer and that its splicing is shifted toward an inactive form in breast cancer. 12 Notably, this study compared the expression of Rbfox2 between solid tumors of epithelial origin and normal tissues, which are composed of mixtures of different cell types. Although these cell type differences might affect differences in the expression of Rbfox2 detected between normal and tumor tissue, our results clearly indicate an upregulation of Rbfox2 during EMT of nontransformed as well as tumorous mammary epithelial cells (Figures 1b and d) . Our data suggest that this upregulation will most likely be a prerequisite for tumor cells to invade the surrounding tissue.
In summary, our results indicate that Rbfox2 is important in establishing the invasive phenotype through its regulation of mesenchymal-specific splicing events during an EMT. Further studies are needed to clarify the role of Rbfox2 during tumor progression in humans and to evaluate Rbfox2 as a potential target for cancer therapy.
MATERIALS AND METHODS
Cell culture
NMuMG, PY2T and MTdeltaEcad cells were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal calf serum, penicillin, streptomycin, glutamine and non-essential amino acids and, in the case of NMuMG cells, insulin. TGFb treatment was performed using 2 ng/ml of TGFb1 (PeproTech, Rocky Hill, NJ, USA; R&D Systems, Minneapolis, MN, USA) and TGFb was replenished every 3 days. Rbfox2 siRNAs were purchased from Dharmacon (Lafayette, CO, USA) and Qiagen (Hilden, Germany) (Supplementary Table S1 ). Transfections using Transfectin (Bio-Rad, Mü nchen, Germany) were carried out according to the manufacturer's instructions.
Antibodies, immunoblotting and immunofluorescence
Cells were lysed by the addition of Magic-Mix (48% urea, 15 mM Tris-HCl (pH 7.5), 8.7% glycerin, 1% sodium dodecyl sulfate, 0.004% bromophenol blue, 143 mM mercaptoethanol), centrifuged through Qia Shredder Columns (Qiagen) and boiled for 5 min at 95 1C. Thirty micrograms of total protein from each sample were resolved on 10% SDS-PAGE (sodium dodecyl sulfate-polyacrylamide gel electrophoresis) gels and blotted onto PVDF membranes. For immunoblotting using the Odyssey system, the gels were blotted and scanned according to the manufacturer's instructions. Immunofluorescence analyses were performed as described previously. 34 The antibodies used in this study were anti-Rbm9 (Bethyl, Montgomery, TX, USA), anti-Vinculin (Sigma-Aldrich, Mü nchen, Germany), anti-Ncadherin (BD Transduction, Lexington, KY), anti-Vimentin (Sigma-Aldrich, Mü nchen, Germany) anti-Gapdh (Chemicon, Temecula, CA, USA), anti-Actin (SigmaAldrich), anti-Smad2/3 (Cell Signaling, Danvers, MA, USA) or anti-PhoshoSmad2 (Cell Signaling).
Quantitative RT-PCR Total RNA from NMuMG and PY2T cells was extracted using the High Pure RNA Isolation kit (Roche, Basel, Switzerland) and reverse transcribed using the RevertAid First Strand cDNA Synthesis kit (Fermentas, St Leon Rot, Germany). The resulting cDNA was used for qPCR analysis using Rox or the Sybr Green Mix (Applied Biosystems, Carlsbad, CA, USA).
Migration assays
Forty-eight hours after transfection with control or Rbfox2 siRNAs, the cells were trypsinized, and 42 000 cells were seeded into each well of culture inserts (Ibidi, Mü nchen, Germany). After 24 h, the inserts were removed, which created a cell-free gap of approximately 500 mm. The cells were observed by phase-contrast microscopy at 16 or 24 h.
For the transwell migration assays, the cells were treated as described for invasion assays and added to control inserts (BD Biocoat Matrigel Invasion Chamber, Becton Dickinson, Heidelberg, Germany) instead of Matrigel-coated inserts.
Invasion assays
Forty-eight hours after transfection with the control or Rbfox2 siRNAs, the cells were trypsinized and 50 000 (NMuMG, MTdeltaEcad) or 25 000 (PY2T) cells were added to Matrigel-coated inserts (BD Biocoat Matrigel Invasion Chamber; Becton Dickinson) in DMEM. These cells were placed in wells containing DMEM, 2% fetal bovine serum (MTdeltaEcad) or DMEM, 2% fetal bovine serum, 5 ng/ml TGFb1 (PeproTech; R&D Systems; NMuMG, PY2T). After 24 h, the cells were removed from the upper surface of the membrane using a cotton-tipped swab. The membranes were fixed in 4% paraformaldehyde for 10 min and mounted using Fluoromount reagent with DAPI (4,6-diamidino-2-phenylindole; Southernbiotech, Birmingham, AL, USA). Rbfox2 and EMT-driven alternative splicing C Braeutigam et al
